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Abstract
Marginal zone lymphoma of the central nervous system (CNS MZL) is rare. The 
clinical features, treatment, and prognosis are not well characterized. We performed 
a multicenter retrospective study of CNS MZL. Twenty-six patients were identified: 
half with primary and half with secondary CNS involvement. The median age was 
59 years (range 26-78), 62% female and 79% with ECOG performance status ≤ 1. 
The most common disease site was the dura (50%). Treatment was determined by the 
treating physician and varied substantially. After a median follow up of 1.9 years, 
the estimated 2-year progression-free (PFS) and overall survival (OS) rates were 
59% and 80%, respectively. Secondary CNS MZL was associated with 2-year OS of 
58%. CNS MZL is rare, but relative to other forms of CNS lymphoma, outcomes ap-
pear favorable, particularly among the subset of patients with dural presentation and 
primary CNS presentation.
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1 |  INTRODUCTION
The 2016 revision of World Health Organization classifi-
cation of lymphoid neoplasms defined marginal zone lym-
phoma (MZL) as a non-Hodgkin lymphoma (NHL) that 
includes three distinct subtypes: extranodal MZL of muco-
sa-associated lymphoid tissue (MALT), nodal, and splenic 
MZL.1 Together, they account for approximately 10% of 
NHL and are the third most common histological subtype 
of NHL after diffuse large B-cell lymphoma (DLBCL) 
and follicular lymphoma.2,3 They are grouped together be-
cause they arise from postgerminal center marginal zone 
B cells and share histopathologic and immunophenotypic 
features.4,5
MZL is considered an indolent lymphoma that typically oc-
curs in association with autoimmune diseases and chronic in-
flammation and was first described by Isaacson and Wright as 
a low-grade lymphoma of gastrointestinal tract MALT.6,7 This 
is the most common site of origin where lymphoproliferation is 
associated with longstanding autoantigenic stimulation due to 
the action of Helicobacter pylori and other microbes.3,8 MZL 
can originate from the mucosa of nongastrointestinal organs 
such as lung, bladder, salivary glands, conjunctiva, and lacrimal 
glands.3 Interestingly, MZL can also develop from tissue sites 
without mucosa including liver, breast, thyroid, orbit, skin, and 
the central nervous system (CNS).3,9 Meningoepithelial cells of 
the arachnoid villi of dural venous sinuses could represent the 
cells of origin of CNS MZL where MALT-type tissue develops 
secondary to chronic inflammation which provides a milieu for 
local accumulation and proliferation of antigen-dependent B 
cells, leading to lymphoma development.10 Due to rarity, the 
clinical features and optimal management of CNS MZL are 
not well defined. To address this, we performed a retrospective 
study to describe the clinical characteristics, prognostic factors, 
treatment, and outcomes of patients with MZL and primary or 
secondary CNS involvement. We recognize that CNS MZL is 
truly defined by the presence of parenchymal and/ or leptome-
ningeal involvement, however, we have included patients with 
dural MZL in this analysis to describe the clinical features and 
response to treatment of this disease also.
2 |  METHODS
We searched institutional databases (MD Anderson Cancer 
Center; Sir Charles Gairdner Hospital; Aalborg University 
Hospital) and regional or national databases (BC Cancer Centre 
for Lymphoid Cancer database, Canada; Swedish Lymphoma 
Registry) to identify patients with CNS MZL who met the fol-
lowing inclusion criteria: (a) histopathologic diagnosis of MZL 
(b) histologically proven MZL of the dura, brain, or leptomenin-
ges, or cytologically proven cerebrospinal fluid involvement at 
any time during disease course and (c) initial diagnosis of MZL 
between 1995 and 2018. Pathology review was performed by 
specialist hematopathologist at each listed center. Those with 
suspected DLBCL were excluded from analysis.
We collected baseline demographic and clinical data, 
treatment, and outcomes. Statistical analysis was performed 
using STATA 14.2 (STATA Corp). In patients with MZL 
and secondary CNS involvement, time to CNS involvement 
was calculated from date of systemic MZL diagnosis to 
date of confirmed CNS involvement. Median observation 
period was calculated from the median observation time of 
patients alive at last follow-up. Overall survival (OS) was 
defined as time from CNS involvement to date of death 
with patients alive at last follow-up censored. Progression-
free survival (PFS) was defined as the time of diagnosis 
of CNS disease to disease progression or death from any 
cause, with patients free from progression at that time point 
censored. Survival data were analyzed using the method of 
Kaplan-Meier. Data collection was compliant with institu-
tional requirements.
3 |  RESULTS
A total of 26 patients with histologically confirmed CNS 
MZL were identified. Clinical features at diagnosis with 
MZL and outcomes are summarized in Table 1. Half had 
primary CNS MZL at diagnosis, whereas the remaining 
half had secondary CNS MZL. Of the 13 patients with 
primary CNS MZL, 12 had biopsy proven MZL and for 
the remaining patient the specific method of detection was 
not documented. For the 13 patients with secondary CNS 
MZL, seven had biopsy proven MZL, whereas the remain-
ing six had cytological evidence of MZL in CSF (3 of these 
had flow cytometric confirmation, for three patients the 
specific method of disease detection beyond cytology was 
not documented).
Of the 26 patients, 16 (62%) were female and the median 
age at diagnosis was 59.5 years (range of 26-78). Most pa-
tients had good performance status at diagnosis (ECOG ≤ 1). 
All patients for which information was available presented 
with focal neurological symptoms including sensory loss, ex-
tremity weakness, visual changes, seizures and/or headaches. 
This is summarized in Table 2. Median duration of symptoms 
prior to CNS diagnosis was 105 days (range 30-420) for pri-
mary disease and 60 days (range 0-930 days) for secondary 
disease. Only two patients (8%) had B type symptoms at pre-
sentation and these patients had secondary CNS MZL stage 
IV disease with leptomeningeal involvement.
Most patients with primary disease had stage I disease 
(n = 11) at time of original diagnosis. One patient with pri-
mary disease had MZL invading the skull and temporalis 
muscle and was classified as stage IV disease. Most patients 
with secondary MZL had stage IV disease (n = 11) at time 
   | 665SUNDERLAND Et AL.
of original diagnosis. The most common anatomical location 
of MZL was disease isolated to dura (50%). This was also 
the most common site of disease for those with primary CNS 
MZL (n = 9, 69%). For those with secondary CNS involve-
ment; four (31%) had disease limited to the dura, whereas 
two (15%) had parenchymal only disease, one (4%) had 
disease limited to the leptomeninges, two (15%) had paren-
chymal + leptomeningeal disease, and one (4%) had leptome-
ningeal + optic nerve involvement. Data were not available 
for disease location for one patient with primary and three 
with secondary CNS involvement.
A minority (n = 7, 27%) of patients presented with ele-
vated serum LDH. All patients, for whom data were available 
(n  =  19), were negative for HIV, Hepatitis B and C. With 
respect to investigations, lumbar puncture was performed 
in 20 cases (77%) and lymphoma cells were detected in the 
cerebrospinal fluid in 3/20 (15%) using cytology and flow 
cytometry. Positron emission tomography (PET) scan was 
performed in 18 cases (69%), for which information was 
available. Magnetic resonance imaging (MRI) of the head 
was performed in all cases for which information was avail-
able (n  =  22) and 20 patients (77%) had unifocal disease, 
whereas two (8%) patients, both with secondary CNS MZL, 
had multifocal disease. Of patients with secondary CNS 
MZL, six (46%) had evidence of bone marrow involvement 
at time of documented CNS dissemination.
Treatment was at the discretion of the treating physi-
cian and is outlined in Table 1. Overall the most common 
treatment was surgery  +  radiotherapy (n  =  7, 27%). For 
primary disease, the most common treatment modality was 
surgery  +  radiotherapy (n  =  5). Treatment data were not 
known for one patient with primary disease. With respect 
to the type of surgery performed, those with dural limited 
disease had complete resection and those with parenchymal 
disease had craniotomy and biopsy. Seven patients with pri-
mary disease that received systemic therapy were treated 
with a combination of methotrexate and/or rituximab (either 
alone or in combination with cyclophosphamide, doxorubi-
cin, vincristine, prednisolone [R-CHOP]). One patient was 
treated with bendamustine, rituximab, and alternating intra-
thecal cytarabine and intrathecal methotrexate. No patient 
with primary disease was treated with radiotherapy or che-
motherapy alone. Table 2 outlines the specific treatment for 
each patient.
Of the 13 patients with secondary CNS MZL, eight 
(62%) had CNS involvement at the time of initial diagno-
sis of MZL. Of the remaining five cases who developed 
CNS involvement at a later stage, four had received treat-
ment prior to diagnosis of CNS. The most common treat-
ment modality for secondary disease was chemotherapy 
alone (n  =  5). Methotrexate, rituximab, and cytarabine 
were used in various combinations for those with sec-
ondary disease. Other combinations included R-CHOP, 
T A B L E  1  Baseline characteristics
Features
Overall 
n = 26 (%)
Primary 
(n = 13)
Secondary 
(n = 13)
Age
Median 59.5 y 51 y 62 y
Range 26-78 y 26-78 y 34-77 y
Sex
Female 16 (62) 9 7
Male 10 (38) 4 6
ECOG
0 16 (62) 9 7
1 7 (27) 3 4
2 1 (4) 1 0
3 2 (8) 0 2
Stage at original MZL diagnosis
I 12 (46) 11 1
II 2 (8) 1 1
III 0 0 0
IV 12 (46) 1 11
B symptoms
Present 2 (8) 0 2
Absent 23 (88) 13 10
Missing 1 (4) 0 1
CNS location
Dural only 13 (50) 9 4
Parenchymal only 5 (19) 3 2
Leptomeningeal only 1 (4) 0 1
Other 3 (12) 0 3
Missing 4 (15) 1 3
Serum LDH
Normal 16 (62) 9 7
Elevated 7 (27) 3 4
Missing 3 (12) 1 2
Treatment
RTx alone 1 (4) 0 1
CTx alone 5 (19) 0 5
SX + RTx 7 (27) 5 2
SX + CTx 6 (23) 4 2
RTx + CTx 0 0 0
SX + RTx +CTx 4 (15) 3 1
Missing 3 (12) 1 2
PF event
No 13 (50) 11 2
Yes 10 (38) 2 8
Missing 3 (12) 0 3
Outcome
Alive 22 (85) 13 9
Dead 4 (15) 0 4
Note: Data expressed as number (percentage).
Abbreviations: CTx, chemotherapy; LDH, lactate dehydrogenase; PF, progres-
sion free; RTx, radiotherapy; SX, surgery.
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fludarabine + cytarabine, ifosfamide + cytarabine +meth-
otrexate, and ibrutinib + rituximab.
For patients with primary CNS MZL, complete CNS re-
sponse was achieved in 10 (77%) of 13 patients. No patient 
with primary disease had systemic progression. For patients 
with secondary disease, only three (23%) of 13 achieved 
complete CNS response. Two of these patients were treated 
with chemotherapy alone, whereas the other was treated with 
all three modalities. Four patients died, all with systemically 
progressive secondary CNS MZL. One died from an acute on 
chronic subdural hemorrhage complicating neutropenic sep-
sis, whereas the remaining three died from progressive lym-
phoma, one of which showed transformation to a high-grade 
lymphoma. All patients with MZL localized to the dura were 
alive at last follow-up. Best CNS response to treatment was 
unknown for four patients (1 with primary disease and 3 with 
secondary).
After a median follow-up time of 1.9  years (range 0.1-
11.4  years), the overall median PFS was not reached with 
2-year PFS of 59% (95%CI:34%-77%) (Figure 1A). The es-
timated 2-year overall survival rate was 80% (95%CI:54%-
92%) (Figure 1B). Overall survival for primary disease at 
2 years was 100%, whereas for secondary CNS MZL this was 
58%.
4 |  DISCUSSION
In this series of patients with MZL, we confirm the relatively 
favorable outcome of primary CNS MZL and report the 
inferior prognosis associated with secondary CNS involve-
ment. CNS MZL typically presents as a solitary mass occupy-
ing lesion that arises from the dura without systemic disease 
involvement.3,11 It is a rare form of primary CNS lymphoma 
(PCNSL) and has a better prognosis compared to the more 
common primary CNS DLBCL.12,13 In a recent SEER anal-
ysis of outcomes of primary CNS lymphoma by histologic 
subtype, the 5-year OS rates were 30% (95%CI:28%-32%) 
for DLBCL and 79% (95%CI:64%-88%) for MZL.12 In this 
study, reported outcomes for CNS MZL were comparable 
with estimated 2-year OS 80% (95%CI:54%-92%). Patients 
with secondary CNS MZL appear less likely to achieve CNS 
complete response, and have inferior PFS and OS. There may 
be some factors that are associated with this inferior OS such 
as the advanced stage of disease at diagnosis, poor perfor-
mance status, B symptoms, and experiencing a progression-
free survival event. Due to limited sample size we did not 
perform univariate analysis so cannot comment on the sta-
tistical significance of these associations compared to those 
with primary CNS MZL.
Due to the rarity of MZL, there have been no trials that 
evaluate different treatment options, and therefore there are 
no standardized treatment regimens for clinicians to utilize. 
There are only a few cases series of secondary MZL in the 
existing literature.3,14,15 With respect to treatment of pri-
mary disease, it is known that MZL is very radiosensitive 
and it has been suggested that patients with disease isolated 
to the dura may not require systemic chemotherapy.16 In 
a combined series from Memorial Sloan Kettering Cancer 
Center and the University of Miami, of 23 patients with 
F I G U R E  1  A, Kaplan-Meir estimate of PFS (in years), B, Kaplan-Meir estimate of OS (in years)
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dural MZL treated after biopsy or surgery, 22 achieved a 
complete remission.17 The majority of patients (87%) re-
ceived cranial directed radiation therapy as a component of 
therapy and the 3-year PFS was 89%.17 Only four patients 
received systemic therapy prompting the authors to con-
clude that complete remission is achievable with focal ther-
apy in this indolent disease. A recent review by Chihara et 
al showed that localized treatment with radiotherapy ± sur-
gery was the most common therapeutic approach for pa-
tients with primary MZL.12 Our data are consistent with 
this.
All patients with primary CNS MZL were alive at me-
dian follow-up time, aligning with the more indolent na-
ture of this disease. Only two patients with primary disease 
did not achieve complete CNS response. Given the lack of 
treatment experience with respect to CNS MZL, and even 
more so with secondary CNS disease, it is not surprising 
that such a range of modalities were chosen based on dis-
ease location and patient characteristics. As opposed to 
radiotherapy ± surgery, chemotherapy was the most com-
mon treatment modality for secondary CNS MZL, in keep-
ing with physician selected treatment for more aggressive 
lymphomas.
The dura was the most common site of CNS MZL in-
volvement, consistent with other case series.13 Cases of 
primary MZL involving the CNS parenchyma and leptome-
ninges are rare.7,9,16 No case of primary CNS MZL in this 
study had leptomeningeal involvement, but three cases in-
volved the parenchyma including the intramedullary cord, 
temporal lobe and basal ganglia. The anatomic location of 
secondary CNS MZL was more varied and suggests that 
MZL with systemic involvement is more heterogenous and 
more likely to involve the parenchyma and leptomeninges. 
It is an important clinical consideration that the majority 
of cases of secondary CNS MZL in this study presented as 
unifocal disease that could easily be mistaken as a primary 
dural lymphoma unless thorough assessment of systemic 
involvement was performed.
Regarding distribution according to sex, we demonstrated 
a female preponderance and that this tendency may be less 
pronounced with respect to secondary MZL where the fe-
male to male ratio was smaller. Another difference between 
primary and secondary disease was the median age of diag-
nosis. Interestingly, there was an 11-year difference between 
the median age of diagnosis for primary (51 years) and sec-
ondary (62 years) disease. Therefore, while the overall me-
dian age of diagnosis in our study (59.5 years) was similar to 
previously published studies, secondary involvement of CNS 
tissue by MZL appeared to occur in a slightly older cohort 
than for primary disease.13 This aligns with the data pub-
lished by Khalil and colleagues on 8,821 cases of MZL from 
multiple anatomical sites that had a median age of diagnosis 
of 66 years.18 The time to CNS diagnosis was also a point of 
difference, however the much shorter duration of symptoms 
prior to detection of CNS disease in patients with second-
ary CNS MZL was unsurprising given these patients had a 
pre-existing diagnosis of MZL or presented with widespread 
symptomatic disease.
There are some limitations to this study. Given the rar-
ity of the disease, the sample size was small which limited 
the application of multivariable analysis. The median fol-
low-up time of 1.9  years could be considered short given 
the range over which patients were assessed. Furthermore, 
due to this long period of inclusion eligibility (1995-2018), 
treatment modalities used may not be reflective of current 
practice. Finally, there were some data points that could not 
be collected.
5 |  CONCLUSION
MZL with secondary CNS involvement has an older age, less 
female predominance, more variable CNS localization and 
inferior prognosis relative to primary CNS MZL. Patients 
with primary MZL have favorable outcomes with radiother-
apy. It also appears that patients with dural location of MZL 
have a better outcome. The optimal treatment of secondary 
CNS MZL remains unclear, though the use of CNS penetrat-
ing chemotherapeutics appears reasonable.
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